Thomson Horstmann & Bryant Inc. boosted its holdings in ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 33.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 20,101 shares of the specialty pharmaceutical company’s stock after buying an additional 5,006 shares during the period. Thomson Horstmann & Bryant Inc. owned approximately 0.17% of ANI Pharmaceuticals worth $1,295,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of ANI Pharmaceuticals by 8.1% during the second quarter. Vanguard Group Inc. now owns 476,948 shares of the specialty pharmaceutical company’s stock worth $22,322,000 after acquiring an additional 35,722 shares in the last quarter. Dimensional Fund Advisors LP increased its position in ANI Pharmaceuticals by 25.2% during the third quarter. Dimensional Fund Advisors LP now owns 424,797 shares of the specialty pharmaceutical company’s stock worth $22,297,000 after acquiring an additional 85,529 shares during the period. Renaissance Technologies LLC increased its position in ANI Pharmaceuticals by 7.0% during the second quarter. Renaissance Technologies LLC now owns 297,400 shares of the specialty pharmaceutical company’s stock worth $13,918,000 after acquiring an additional 19,400 shares during the period. Northern Trust Corp increased its holdings in ANI Pharmaceuticals by 5.2% in the 2nd quarter. Northern Trust Corp now owns 112,905 shares of the specialty pharmaceutical company’s stock valued at $5,285,000 after buying an additional 5,599 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in ANI Pharmaceuticals by 868.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 104,829 shares of the specialty pharmaceutical company’s stock valued at $5,404,000 after buying an additional 94,002 shares during the period. Institutional investors and hedge funds own 55.05% of the company’s stock.
Several research firms have commented on ANIP. BidaskClub raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, January 5th. Canaccord Genuity set a $77.00 target price on shares of ANI Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, December 29th. Zacks Investment Research downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. ValuEngine downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, December 20th. Finally, TheStreet upgraded shares of ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Thursday, November 16th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $71.00.
Shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) opened at $69.74 on Friday. ANI Pharmaceuticals Inc has a one year low of $42.23 and a one year high of $74.70. The company has a debt-to-equity ratio of 0.83, a quick ratio of 2.39 and a current ratio of 3.45. The company has a market cap of $827.25, a price-to-earnings ratio of 108.97 and a beta of 2.90.
ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.12. The business had revenue of $48.16 million for the quarter, compared to the consensus estimate of $48.12 million. ANI Pharmaceuticals had a net margin of 4.45% and a return on equity of 22.40%. The company’s revenue was up 25.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.09 earnings per share. equities research analysts forecast that ANI Pharmaceuticals Inc will post 3.59 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/19/thomson-horstmann-bryant-inc-has-1-30-million-position-in-ani-pharmaceuticals-inc-anip.html.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.